Branded urofollitropin

Pharmasure has launched Fostimon (urofollitropin), licensed for the treatment of anovulatory infertility unresponsive to clomifene, and controlled ovarian hyperstimulation to induce multiple follicles for IVF, GIFT and ZIFT.

Fostimon is a highly purified follicle stimulating hormone (FSH), obtained from human menopausal gonadotropin (HMG). The main effect of FSH is the development and maturation of de Graaf follicles.

Fostimon is available in two strengths, 75iu and 150iu, and is presented in packs of 10 vials (plus solvent in ampoules) for reconstitution. The most commonly reported adverse effects include ovarian hyperstimulation, headache, constipation, abdominal distension and pain.

Further information: Pharmasure 01923 233113

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Pregnant woman having an ultrasound scan with a female sonographer

Valproate prescribing: plan for new regulatory measures without delay, instructs MHRA

A National Patient Safety Alert (NatPSA) has been issued...

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...

New and deleted indications - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest changes to...

Drug shortages - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...